Global Non-oncology Biopharmaceuticals Market 2021 by Company, Regions, Type and Applicat...

  • Report ID:72246
  • Industry Name: Pharma & Healthcare
  • Publishing Date: Jun-21
  • No. of Pages: 123
                              
The Non-oncology Biopharmaceuticals market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations. According to our latest research, the global Non-oncology Biopharmaceuticals size is estimated to be USD 412960 million in 2026 from USD 304180 million in 2020, with a change XX% between 2020 and 2021. The global Non-oncology Biopharmaceuticals market size is expected to grow at a CAGR of 7.9% for the next five years. Market segmentation Non-oncology Biopharmaceuticals market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type, covers Biologics Biosimilars Market segment by Application, can be divided into Immunology Endocrinology Others Market segment by players, this report covers Roche Sanofi Johnson & Johnson Pfizer Novo Nordisk Novartis Merck Teva Eli Lilly Bristol-Myers Squibb GlaxoSmithKline UCB Pharma Amgen AbbVie Takeda AstraZeneca Mylan LEO Pharma Boehringer Ingelheim Alexion Pharmaceuticals Elusys Therapeutics Swedish Orphan Biovitrum Biogen Market segment by regions, regional analysis covers North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific) South America (Brazil, Argentina, Rest of South America) Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
                        
1 Market Overview 1.1 Product Overview and Scope of Non-oncology Biopharmaceuticals 1.2 Classification of Non-oncology Biopharmaceuticals by Type 1.2.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Type: 2020 Versus 2021 Versus 2026 1.2.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2020 1.2.3 Biologics 1.2.4 Biosimilars 1.3 Global Non-oncology Biopharmaceuticals Market by Application 1.3.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Application: 2020 Versus 2021 Versus 2026 1.3.2 Immunology 1.3.3 Endocrinology 1.3.4 Others 1.4 Global Non-oncology Biopharmaceuticals Market Size & Forecast 1.5 Global Non-oncology Biopharmaceuticals Market Size and Forecast by Region 1.5.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2016 VS 2021 VS 2026 1.5.2 Global Non-oncology Biopharmaceuticals Market Size by Region, (2016-2021) 1.5.3 North America Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026) 1.5.4 Europe Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026) 1.5.5 Asia-Pacific Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026) 1.5.6 South America Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026) 1.5.7 Middle East and Africa Non-oncology Biopharmaceuticals Market Size and Prospect (2016-2026) 1.6 Market Drivers, Restraints and Trends 1.6.1 Non-oncology Biopharmaceuticals Market Drivers 1.6.2 Non-oncology Biopharmaceuticals Market Restraints 1.6.3 Non-oncology Biopharmaceuticals Trends Analysis 2 Company Profiles 2.1 Roche 2.1.1 Roche Details 2.1.2 Roche Major Business 2.1.3 Roche Non-oncology Biopharmaceuticals Product and Solutions 2.1.4 Roche Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.1.5 Roche Recent Developments and Future Plans 2.2 Sanofi 2.2.1 Sanofi Details 2.2.2 Sanofi Major Business 2.2.3 Sanofi Non-oncology Biopharmaceuticals Product and Solutions 2.2.4 Sanofi Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.2.5 Sanofi Recent Developments and Future Plans 2.3 Johnson & Johnson 2.3.1 Johnson & Johnson Details 2.3.2 Johnson & Johnson Major Business 2.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions 2.3.4 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.3.5 Johnson & Johnson Recent Developments and Future Plans 2.4 Pfizer 2.4.1 Pfizer Details 2.4.2 Pfizer Major Business 2.4.3 Pfizer Non-oncology Biopharmaceuticals Product and Solutions 2.4.4 Pfizer Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.4.5 Pfizer Recent Developments and Future Plans 2.5 Novo Nordisk 2.5.1 Novo Nordisk Details 2.5.2 Novo Nordisk Major Business 2.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions 2.5.4 Novo Nordisk Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.5.5 Novo Nordisk Recent Developments and Future Plans 2.6 Novartis 2.6.1 Novartis Details 2.6.2 Novartis Major Business 2.6.3 Novartis Non-oncology Biopharmaceuticals Product and Solutions 2.6.4 Novartis Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.6.5 Novartis Recent Developments and Future Plans 2.7 Merck 2.7.1 Merck Details 2.7.2 Merck Major Business 2.7.3 Merck Non-oncology Biopharmaceuticals Product and Solutions 2.7.4 Merck Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.7.5 Merck Recent Developments and Future Plans 2.8 Teva 2.8.1 Teva Details 2.8.2 Teva Major Business 2.8.3 Teva Non-oncology Biopharmaceuticals Product and Solutions 2.8.4 Teva Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.8.5 Teva Recent Developments and Future Plans 2.9 Eli Lilly 2.9.1 Eli Lilly Details 2.9.2 Eli Lilly Major Business 2.9.3 Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions 2.9.4 Eli Lilly Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.9.5 Eli Lilly Recent Developments and Future Plans 2.10 Bristol-Myers Squibb 2.10.1 Bristol-Myers Squibb Details 2.10.2 Bristol-Myers Squibb Major Business 2.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions 2.10.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.10.5 Bristol-Myers Squibb Recent Developments and Future Plans 2.11 GlaxoSmithKline 2.11.1 GlaxoSmithKline Details 2.11.2 GlaxoSmithKline Major Business 2.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions 2.11.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.11.5 GlaxoSmithKline Recent Developments and Future Plans 2.12 UCB Pharma 2.12.1 UCB Pharma Details 2.12.2 UCB Pharma Major Business 2.12.3 UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions 2.12.4 UCB Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.12.5 UCB Pharma Recent Developments and Future Plans 2.13 Amgen 2.13.1 Amgen Details 2.13.2 Amgen Major Business 2.13.3 Amgen Non-oncology Biopharmaceuticals Product and Solutions 2.13.4 Amgen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.13.5 Amgen Recent Developments and Future Plans 2.14 AbbVie 2.14.1 AbbVie Details 2.14.2 AbbVie Major Business 2.14.3 AbbVie Non-oncology Biopharmaceuticals Product and Solutions 2.14.4 AbbVie Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.14.5 AbbVie Recent Developments and Future Plans 2.15 Takeda 2.15.1 Takeda Details 2.15.2 Takeda Major Business 2.15.3 Takeda Non-oncology Biopharmaceuticals Product and Solutions 2.15.4 Takeda Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.15.5 Takeda Recent Developments and Future Plans 2.16 AstraZeneca 2.16.1 AstraZeneca Details 2.16.2 AstraZeneca Major Business 2.16.3 AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions 2.16.4 AstraZeneca Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.16.5 AstraZeneca Recent Developments and Future Plans 2.17 Mylan 2.17.1 Mylan Details 2.17.2 Mylan Major Business 2.17.3 Mylan Non-oncology Biopharmaceuticals Product and Solutions 2.17.4 Mylan Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.17.5 Mylan Recent Developments and Future Plans 2.18 LEO Pharma 2.18.1 LEO Pharma Details 2.18.2 LEO Pharma Major Business 2.18.3 LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions 2.18.4 LEO Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.18.5 LEO Pharma Recent Developments and Future Plans 2.19 Boehringer Ingelheim 2.19.1 Boehringer Ingelheim Details 2.19.2 Boehringer Ingelheim Major Business 2.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions 2.19.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.19.5 Boehringer Ingelheim Recent Developments and Future Plans 2.20 Alexion Pharmaceuticals 2.20.1 Alexion Pharmaceuticals Details 2.20.2 Alexion Pharmaceuticals Major Business 2.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions 2.20.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.20.5 Alexion Pharmaceuticals Recent Developments and Future Plans 2.21 Elusys Therapeutics 2.21.1 Elusys Therapeutics Details 2.21.2 Elusys Therapeutics Major Business 2.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions 2.21.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.21.5 Elusys Therapeutics Recent Developments and Future Plans 2.22 Swedish Orphan Biovitrum 2.22.1 Swedish Orphan Biovitrum Details 2.22.2 Swedish Orphan Biovitrum Major Business 2.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions 2.22.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.22.5 Swedish Orphan Biovitrum Recent Developments and Future Plans 2.23 Biogen 2.23.1 Biogen Details 2.23.2 Biogen Major Business 2.23.3 Biogen Non-oncology Biopharmaceuticals Product and Solutions 2.23.4 Biogen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019-2021) 2.23.5 Biogen Recent Developments and Future Plans 3 Market Competition, by Players 3.1 Global Non-oncology Biopharmaceuticals Revenue and Share by Players (2019-2021) 3.2 Market Concentration Rate 3.2.1 Top 3 Non-oncology Biopharmaceuticals Players Market Share 3.2.2 Top 10 Non-oncology Biopharmaceuticals Players Market Share 3.2.3 Market Competition Trend 3.3 Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided 3.4 Mergers & Acquisitions 3.5 New Entrants and Expansion Plans 4 Market Size Segment by Type 4.1 Global Non-oncology Biopharmaceuticals Revenue and Market Share by Type (2016-2021) 4.2 Global Non-oncology Biopharmaceuticals Market Forecast by Type (2021-2026) 5 Market Size Segment by Application 5.1 Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2016-2021) 5.2 Non-oncology Biopharmaceuticals Market Forecast by Application (2021-2026) 6 North America by Country, by Type, and by Application 6.1 North America Non-oncology Biopharmaceuticals Revenue by Type (2016-2026) 6.2 North America Non-oncology Biopharmaceuticals Revenue by Application (2016-2026) 6.3 North America Non-oncology Biopharmaceuticals Market Size by Country 6.3.1 North America Non-oncology Biopharmaceuticals Revenue by Country (2016-2026) 6.3.2 United States Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 6.3.3 Canada Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 6.3.4 Mexico Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 7 Europe by Country, by Type, and by Application 7.1 Europe Non-oncology Biopharmaceuticals Revenue by Type (2016-2026) 7.2 Europe Non-oncology Biopharmaceuticals Revenue by Application (2016-2026) 7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country 7.3.1 Europe Non-oncology Biopharmaceuticals Revenue by Country (2016-2026) 7.3.2 Germany Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 7.3.3 France Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 7.3.4 United Kingdom Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 7.3.5 Russia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 7.3.6 Italy Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 8 Asia-Pacific by Region, by Type, and by Application 8.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2016-2026) 8.2 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2016-2026) 8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region 8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2016-2026) 8.3.2 China Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 8.3.3 Japan Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 8.3.4 South Korea Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 8.3.5 India Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 8.3.6 Southeast Asia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 8.3.7 Australia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 9 South America by Country, by Type, and by Application 9.1 South America Non-oncology Biopharmaceuticals Revenue by Type (2016-2026) 9.2 South America Non-oncology Biopharmaceuticals Revenue by Application (2016-2026) 9.3 South America Non-oncology Biopharmaceuticals Market Size by Country 9.3.1 South America Non-oncology Biopharmaceuticals Revenue by Country (2016-2026) 9.3.2 Brazil Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 9.3.3 Argentina Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 10 Middle East & Africa by Country, by Type, and by Application 10.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2016-2026) 10.2 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2016-2026) 10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country 10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2016-2026) 10.3.2 Turkey Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 10.3.3 Saudi Arabia Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 10.3.4 UAE Non-oncology Biopharmaceuticals Market Size and Forecast (2016-2026) 11 Research Findings and Conclusion 12 Appendix 12.1 Methodology 12.2 Research Process and Data Source 12.3 Disclaimer
                
List of Tables Table 1. Global Non-oncology Biopharmaceuticals Revenue by Type, (USD Million), 2020 VS 2021 VS 2026 Table 2. Global Non-oncology Biopharmaceuticals Revenue by Application, (USD Million), 2020 VS 2021 VS 2026 Table 3. Global Market Non-oncology Biopharmaceuticals Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026) Table 4. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Region (2016-2021) Table 5. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2021-2026) Table 6. Roche Corporate Information, Head Office, and Major Competitors Table 7. Roche Major Business Table 8. Roche Non-oncology Biopharmaceuticals Product and Solutions Table 9. Roche Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 10. Sanofi Corporate Information, Head Office, and Major Competitors Table 11. Sanofi Major Business Table 12. Sanofi Non-oncology Biopharmaceuticals Product and Solutions Table 13. Sanofi Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 14. Johnson & Johnson Corporate Information, Head Office, and Major Competitors Table 15. Johnson & Johnson Major Business Table 16. Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions Table 17. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 18. Pfizer Corporate Information, Head Office, and Major Competitors Table 19. Pfizer Major Business Table 20. Pfizer Non-oncology Biopharmaceuticals Product and Solutions Table 21. Pfizer Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 22. Novo Nordisk Corporate Information, Head Office, and Major Competitors Table 23. Novo Nordisk Major Business Table 24. Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions Table 25. Novo Nordisk Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 26. Novartis Corporate Information, Head Office, and Major Competitors Table 27. Novartis Major Business Table 28. Novartis Non-oncology Biopharmaceuticals Product and Solutions Table 29. Novartis Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 30. Merck Corporate Information, Head Office, and Major Competitors Table 31. Merck Major Business Table 32. Merck Non-oncology Biopharmaceuticals Product and Solutions Table 33. Merck Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 34. Teva Corporate Information, Head Office, and Major Competitors Table 35. Teva Major Business Table 36. Teva Non-oncology Biopharmaceuticals Product and Solutions Table 37. Teva Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 38. Eli Lilly Corporate Information, Head Office, and Major Competitors Table 39. Eli Lilly Major Business Table 40. Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions Table 41. Eli Lilly Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 42. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors Table 43. Bristol-Myers Squibb Major Business Table 44. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions Table 45. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors Table 47. GlaxoSmithKline Major Business Table 48. GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions Table 49. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 50. UCB Pharma Corporate Information, Head Office, and Major Competitors Table 51. UCB Pharma Major Business Table 52. UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions Table 53. UCB Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 54. Amgen Corporate Information, Head Office, and Major Competitors Table 55. Amgen Major Business Table 56. Amgen Non-oncology Biopharmaceuticals Product and Solutions Table 57. Amgen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 58. AbbVie Corporate Information, Head Office, and Major Competitors Table 59. AbbVie Major Business Table 60. AbbVie Non-oncology Biopharmaceuticals Product and Solutions Table 61. AbbVie Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 62. Takeda Corporate Information, Head Office, and Major Competitors Table 63. Takeda Major Business Table 64. Takeda Non-oncology Biopharmaceuticals Product and Solutions Table 65. Takeda Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 66. AstraZeneca Corporate Information, Head Office, and Major Competitors Table 67. AstraZeneca Major Business Table 68. AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions Table 69. AstraZeneca Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 70. Mylan Corporate Information, Head Office, and Major Competitors Table 71. Mylan Major Business Table 72. Mylan Non-oncology Biopharmaceuticals Product and Solutions Table 73. Mylan Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 74. LEO Pharma Corporate Information, Head Office, and Major Competitors Table 75. LEO Pharma Major Business Table 76. LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions Table 77. LEO Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 78. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors Table 79. Boehringer Ingelheim Major Business Table 80. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions Table 81. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 82. Alexion Pharmaceuticals Corporate Information, Head Office, and Major Competitors Table 83. Alexion Pharmaceuticals Major Business Table 84. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions Table 85. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 86. Elusys Therapeutics Corporate Information, Head Office, and Major Competitors Table 87. Elusys Therapeutics Major Business Table 88. Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions Table 89. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 90. Swedish Orphan Biovitrum Corporate Information, Head Office, and Major Competitors Table 91. Swedish Orphan Biovitrum Major Business Table 92. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions Table 93. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 94. Biogen Corporate Information, Head Office, and Major Competitors Table 95. Biogen Major Business Table 96. Biogen Non-oncology Biopharmaceuticals Product and Solutions Table 97. Biogen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 98. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Players (2019-2021) Table 99. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2019-2021) Table 100. Breakdown of Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2 and Tier 3) Table 101. Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided Table 102. Non-oncology Biopharmaceuticals Mergers & Acquisitions in the Past Five Years Table 103. Non-oncology Biopharmaceuticals New Entrants and Expansion Plans Table 104. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Type (2016-2021) Table 105. Global Non-oncology Biopharmaceuticals Revenue Share by Type (2016-2021) Table 106. Global Non-oncology Biopharmaceuticals Revenue Forecast by Type (2021-2026) Table 107. Global Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) Table 108. Global Non-oncology Biopharmaceuticals Revenue Forecast by Application (2021-2026) Table 109. North America Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million) Table 110. North America Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million) Table 111. North America Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million) Table 112. North America Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million) Table 113. North America Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million) Table 114. North America Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million) Table 115. Europe Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million) Table 116. Europe Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million) Table 117. Europe Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million) Table 118. Europe Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million) Table 119. Europe Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million) Table 120. Europe Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million) Table 121. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million) Table 122. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million) Table 123. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million) Table 124. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million) Table 125. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2016-2021) & (USD Million) Table 126. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2021-2026) & (USD Million) Table 127. South America Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million) Table 128. South America Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million) Table 129. South America Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million) Table 130. South America Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million) Table 131. South America Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million) Table 132. South America Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million) Table 133. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2016-2021) & (USD Million) Table 134. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (USD Million) Table 135. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2016-2021) & (USD Million) Table 136. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (USD Million) Table 137. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2016-2021) & (USD Million) Table 138. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (USD Million) List of Figures Figure 1. Non-oncology Biopharmaceuticals Picture Figure 2. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2020 Figure 3. Biologics Figure 4. Biosimilars Figure 5. Non-oncology Biopharmaceuticals Revenue Market Share by Application in 2020 Figure 6. Immunology Picture Figure 7. Endocrinology Picture Figure 8. Others Picture Figure 9. Global Non-oncology Biopharmaceuticals Revenue, (USD Million): 2020 VS 2021 VS 2026 Figure 10. Global Non-oncology Biopharmaceuticals Revenue and Forecast (2016-2026) & (USD Million) Figure 11. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2016-2026) Figure 12. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region in 2020 Figure 13. North America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026) Figure 14. Europe Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026) Figure 15. Asia-Pacific Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026) Figure 16. South America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026) Figure 17. Middle East and Africa Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2016-2026) Figure 18. Non-oncology Biopharmaceuticals Market Drivers Figure 19. Non-oncology Biopharmaceuticals Market Restraints Figure 20. Non-oncology Biopharmaceuticals Market Trends Figure 21. Roche Recent Developments and Future Plans Figure 22. Sanofi Recent Developments and Future Plans Figure 23. Johnson & Johnson Recent Developments and Future Plans Figure 24. Pfizer Recent Developments and Future Plans Figure 25. Novo Nordisk Recent Developments and Future Plans Figure 26. Novartis Recent Developments and Future Plans Figure 27. Merck Recent Developments and Future Plans Figure 28. Teva Recent Developments and Future Plans Figure 29. Eli Lilly Recent Developments and Future Plans Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans Figure 31. GlaxoSmithKline Recent Developments and Future Plans Figure 32. UCB Pharma Recent Developments and Future Plans Figure 33. Amgen Recent Developments and Future Plans Figure 34. AbbVie Recent Developments and Future Plans Figure 35. Takeda Recent Developments and Future Plans Figure 36. AstraZeneca Recent Developments and Future Plans Figure 37. Mylan Recent Developments and Future Plans Figure 38. LEO Pharma Recent Developments and Future Plans Figure 39. Boehringer Ingelheim Recent Developments and Future Plans Figure 40. Alexion Pharmaceuticals Recent Developments and Future Plans Figure 41. Elusys Therapeutics Recent Developments and Future Plans Figure 42. Swedish Orphan Biovitrum Recent Developments and Future Plans Figure 43. Biogen Recent Developments and Future Plans Figure 44. Global Non-oncology Biopharmaceuticals Revenue Share by Players in 2020 Figure 45. Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3) Figure 46. Global Top 3 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2020 Figure 47. Global Top 10 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2020 Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021) Figure 49. Global Non-oncology Biopharmaceuticals Revenue Share by Type in 2020 Figure 50. Global Non-oncology Biopharmaceuticals Market Share Forecast by Type (2021-2026) Figure 51. Global Non-oncology Biopharmaceuticals Revenue Share by Application in 2020 Figure 52. Global Non-oncology Biopharmaceuticals Market Share Forecast by Application (2021-2026) Figure 53. North America Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026) Figure 54. North America Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026) Figure 55. North America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026) Figure 56. United States Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 57. Canada Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 58. Mexico Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 59. Europe Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026) Figure 60. Europe Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026) Figure 61. Europe Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026) Figure 62. Germany Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 63. France Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 64. United Kingdom Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 65. Russia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 66. Italy Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 67. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026) Figure 68. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026) Figure 69. Asia-Pacific Non-oncology Biopharmaceuticals Revenue Market Share by Region (2016-2026) Figure 70. China Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 71. Japan Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 72. South Korea Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 73. India Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 74. Southeast Asia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 75. Australia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 76. South America Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026) Figure 77. South America Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026) Figure 78. South America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026) Figure 79. Brazil Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 80. Argentina Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 81. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Type (2016-2026) Figure 82. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Application (2016-2026) Figure 83. Middle East and Africa Non-oncology Biopharmaceuticals Revenue Market Share by Country (2016-2026) Figure 84. Turkey Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 85. Saudi Arabia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 86. UAE Non-oncology Biopharmaceuticals Revenue and Growth Rate (2016-2026) & (USD Million) Figure 87. Methodology Figure 88. Research Process and Data Source

Purchase Report

Single User 3480
Multi User 5220
Corporate User 6960
Buy

Purchase Report

Customize the purchase as per your specific research needs:

  • 20% additional customization
  • Request for country level reports
  • Request for historical statistics
  • Additional company profile on request

Why Choose Our Report?

24/5 Research support

Get your queries resolved from an industry expert

Custom research service

Design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.